Sanofi
Compounds as peptidic GLP1/glucagon/GIP receptor agonists
Last updated:
Abstract:
The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
Status:
Grant
Type:
Utility
Filling date:
1 Dec 2017
Issue date:
31 Dec 2019